1. Home
  2. MFA vs NVCR Comparison

MFA vs NVCR Comparison

Compare MFA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$10.27

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$12.14

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
NVCR
Founded
1997
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MFA
NVCR
Price
$10.27
$12.14
Analyst Decision
Buy
Buy
Analyst Count
6
6
Target Price
$11.05
$28.08
AVG Volume (30 Days)
1.2M
981.7K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
13.91%
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
$10.02
$6.74
P/E Ratio
$7.75
N/A
Revenue Growth
N/A
8.28
52 Week Low
$8.78
$9.82
52 Week High
$10.57
$20.05

Technical Indicators

Market Signals
Indicator
MFA
NVCR
Relative Strength Index (RSI) 59.83 52.05
Support Level $9.75 $10.72
Resistance Level $10.33 $13.30
Average True Range (ATR) 0.16 0.58
MACD 0.04 0.11
Stochastic Oscillator 79.84 63.54

Price Performance

Historical Comparison
MFA
NVCR

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: